Rising PSA after a radical treatment

European Urology

Volumn 40, Issue SUPPL. 2, 2001, Pages 9-16

  Carroll, Peter ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Prostate cancer; Prostatectomy; PSA; Radiotherapy

Indexed keywords

ANDROGEN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; BIOCHEMISTRY; BLOOD ANALYSIS; BONE SCINTISCANNING; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CRYOSURGERY; HUMAN; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; SALVAGE THERAPY; SURGICAL TECHNIQUE; TREATMENT FAILURE;

EID: 0035743204     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049879     Document Type: Conference Paper

References (60)

1. Temporal trends in rates of prostate cancer: Declining incidence of advanced stage disease, 1974 to 1994
2. Diagnosis and staging of prostate cancer
3. Radical retropubic prostatectomy for localized prostate cancer
4. Radiation therapy in the treatment of localized/organ-confined prostate cancer
5. The role of cryosurgery in the treatment of prostate cancer
6. Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma
7. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer
8. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden
9. Prostate specific antigen only progression of prostate cancer
10. Use of second treatment following definitive local therapy for prostate cancer: Data from the caPSURE database
11. Follow-up prostate cancer treatments after radical prostatectomy: A population-based study
12. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience 1988-1990 (updated June 1993)
13. Outcomes of external-beam radiation therapy for prostate cancer: A study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas
14. Natural history of progression after PSA elevation following radical prostatectomy
15. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer
16. Radical prostatectomy
17. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer
18. Radical prostatectomy for adenocarcinoma of the prostate: The influence of preoperative and pathologic findings on biochemical disease-free outcome
19. 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer
20. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer?
21. PSA recurrence after definitive treatment of clinically localized prostate cancer
22. Pathology of adenocarcinoma of the prostate
23. Systematic sextant biopsies in the prediction of extracapsular extension at radical prostatectomy
24. Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy
25. Ability of sextant biopsies to predict radical prostatectomy stage
26. PSA after definitive radiotherapy for clinically localized prostate cancer
27. Incidence and significance of positive margins in radical prostatectomy specimens
28. Disease progression following radical prostatectomy in men with Gleason score 7 tumor
29. The clinical usefulness of prostate specific antigen: Update 1994
30. Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen
31. The value of serum prostate specific antigen determinations before and after radical prostatectomy
32. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases
33. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy
34. Prostate-specific antigen 1998: What we have learned and where we are going. Part II: Detection, staging, and monitoring of prostate cancer
35. Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy
36. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma
37. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer
38. Prostate-specific antigen nadir of 0.5 ng/ml or less defines disease freedom for surgically staged men irradiated for prostate cancer
39. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation
40. The efficacy of cryosurgical ablation of prostate cancer: The University of California, San Francisco experience
41. Serum PSA as a tumor marker for patients undergoing definitive radiation therapy
42. Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy - A phase III EORTC study
43. Predicting long-term survival, and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials
44. Is anastomotic biopsy necessary prior to radiotherapy after radical prostatectomy?
45. Adjuvant radiotherapy following radical prostatectomy: Results and complications
46. Definitive radiotherapy following prostatectomy: Results and complications
47. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy
48. Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy
49. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer
50. Radiotherapy after radical prostatectomy: Treatment outcomes and failure patterns
51. Consensus statement guidelines for PSA following radiation therapy
52. Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate rebiopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy
53. Management of a positive surgical margin after radical prostatectomy: Decision analysis
54. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin
55. Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer
56. Role of surgery in managing local recurrence following external-beam radiation therapy
57. Salvage radical prostatectomy: Outcome measured by serum prostate specific antigen levels
58. Short-term outcomes after cryo-surgical ablation of the prostate in men with recurrent prostate carcinoma following radiation therapy
59. Predictive value of prostate specific antigen nadir after salvage cryotherapy
60. Permanent brachytherapy as salvage treatment for recurrent prostate cancer